Condition: Follicular Lymphoma · Sponsor: Juan P. Alderuccio, MD
The purpose of this research is to see if Loncastuximab Tesirine in combination with Rituximab will result in higher complete response rate when given to treat follicular lymphoma.
This description comes directly from the study's public registry record.
Juan P Alderuccio, MD · 305-243-5995 · jalderuccio@med.miami.edu
Always discuss trial participation with your own doctor first.
| Florida Cancer Specialists and Research Institute | Fort Myers, Florida, United States | Not Yet Recruiting |
| University of Miami | Miami, Florida, United States | Recruiting |
| University of Michigan | Ann Arbor, Michigan, United States | Recruiting |
| Rutgers Cancer Institute of New Jersey | New Brunswick, New Jersey, United States | Recruiting |
| Allegheny Health Network | Pittsburgh, Pennsylvania, United States | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04998669